The consortium is coordinated by the International Agency for Research on Cancer with the aim of sharing data from ongoing lung cancer case-control and cohort studies.

The therapy, P-BCMA-ALL01, demonstrated a 91% overall response rate for the 23 patients participating in the phase 1 trial.

The event brings physician-scientists, resident physicians, MD, MD/PhD and undergraduate students together to promote mentorship, provide information and showcase student research.

The study seeks to understand the mechanisms of colorectal cancer and builds on recent Vanderbilt research.

The project seeks to reduce the time for clinical chart abstraction by 90% while maintaining human-level accuracy.

VUMC researchers have developed a genetic method that clusters distantly related people to find rare variants that were present in a common ancestor.

Launched Sept. 17-19 during the World Cancer Congress in Geneva, Switzerland, “Rewriting Cancer” aims to enhance understanding and inspire audiences by exploring the most innovative, inclusive and impactful solutions for cancer prevention, diagnosis, treatment and care globally.